We at @CureSHANK are so pleased to award @J_S_Farrell with our first Research-to-Cure Grant, focused on #SHANK3-related #epilepsy, a heartbreaking symptom of #phelanmcdermidsyndrome. Jordan's research aims to narrow the scope of future therapies to more selective targets.
It’s been quite a journey to get this out there, and it is finally out.
Key lesson: Black men are not hard to reach, you are failing to reach them. Get creative.
https://t.co/T5YtizuPtV
The 2024 @alzassociation Facts and Figures Report just dropped today! It was an honor to be part of the process of writing this important report 🧠💜 #AlzheimersInAmerica https://t.co/Cfr21IJx81
Very happy to share our latest work from the @SolteszLab co-led w/ @EHwaun now online at @Nature. We take a deep dive into a neural activity pattern known as the hippocampal "dentate spike" and its role in cognition. https://t.co/tNhtK2ObqE
DSI is a form of synaptic plasticity mediated by endocannabinoids (eCBs). With @LinlinZFan, we demonstrated in vivo that place cell activity triggers eCB signals affecting GABAergic inputs; and that cannabinoid receptors modulate place cell tuning.
https://t.co/3Lbq50ggWu
Welcome to the ELHA Lab! ELHA is a tribute to Estrella Ortíz Romero. We are here to work in partnership with Latino-Hispanic communities on Alzheimer's prevention. 🦋🧠💜 #ELHA#HealthyAging#LegacyOfLove
Dr. Keith Vossel, Director of the Easton Center, was quoted in a July 17th Healthline article commented on an observational study that revealed maintaining a socially and mentally active lifestyle in late life reduces the risk of dementia.
https://t.co/lmzajyuN3a
Mariane Vicente, PhD, postdoctoral fellow in the Vossel lab, presented her latest findings on tau and epileptic activity to a packed audience at AAIC 2023.
Dr. Keith Vossel, Neurologist and Director of the Easton Center, was quoted in a Washington Post article on July 6th about how dementia experts will need additional visit time with patients qualified for Leqembi.
https://t.co/lIQWShefar
Are you interested in participating in a clinical trial for #Alzheimers with UCLA Easton Center? Call us to find out if you are a match for a study. (310) 794-6191 or visit https://t.co/eiHEy6CAN2.
In prodromal stages of Alzheimer’s disease, RSC hypometabolism seems to predict cognitive impairment
Using a mouse model of AD, we identify sex-specific impairments in PV-INs in the RSC and provide a specific target for early therapeutic intervention
https://t.co/pJOTI2bAxZ
Clinical trial participants have the unique opportunity to help scientists conduct research and find novel treatments. You can further #Alzheimers research by calling (310) 794-6191 or visiting https://t.co/9bYYSYm1LU.
Dr. Keith Vossel, Neurologist and Director of the Easton Center, was interviewed by DailyMail about some of the behaviors and emotional changes that patients and caregivers face with frontotemporal dementia, typically before the age of 60.
#FTD
https://t.co/iZMvMNlPBf
Dr. Timothy Chang and Dr. Jessica Rexach of UCLA were among the speakers from USC, Cedars-Sinai, UCSD, and UCI to present at the 2023 SoCal #Alzheimer’s Disease Research Center Collaborative Conference on Wednesday, May 10th, at UCI.
Dr. Keith Vossel, Director of the UCLA Easton Center, was interviewed by MarketWatch on May 3rd, about his perception of the new #Alzheimer’s medication, #donanemab, by Eli Lilly, and the unknown costs associated with the drug and related tests.
https://t.co/GPLvz27eKI